Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma: Clinical article

Kenneth L. Hill, Adam C. Lipson, Jonas M. Sheehan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Object. The authors report novel imaging findings associated with the treatment of sorafenib (Nexavar) and sunitinib (Sutant), 2 agents used in the treatment of advanced metastatic disease. Methods. Patients with renal cell and breast carcinoma metastases to the brain were identified from the prospective database at the Penn State Hershey Medical Center and Penn State Cancer Institute. Results. Four patients who received sorafenib or sunitinib after surgical or radiosurgical treatment of their metastases were identified from the database. Clinical and/or radiographic changes consisting of seizures and cognitive or motor changes were described, associated with an increase in peritumoral edema and enhancement. These findings were observed to improve with discontinuation of the medications. Conclusions. The administration of sorafenib and sunitinib in patients with metastatic breast and renal cell carcinoma may lead to reversible clinical and imaging changes following surgical or radiosurgical treatment of their brain lesions. The authors hypothesize that leakage of the drug across a locally impaired blood-brain barrier contributes to peritumoral edema and inflammation, which may be erroneously interpreted as disease progression.

Original languageEnglish (US)
Pages (from-to)497-503
Number of pages7
JournalJournal of neurosurgery
Volume111
Issue number3
DOIs
StatePublished - Dec 7 2009

Fingerprint

Renal Cell Carcinoma
Magnetic Resonance Imaging
Breast Neoplasms
Drug Therapy
Brain
Edema
Databases
Neoplasm Metastasis
Therapeutics
Blood-Brain Barrier
Disease Progression
Seizures
Breast
Inflammation
sunitinib
sorafenib
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

@article{ea66ae77efd44b3db923daf4aaf97cbf,
title = "Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma: Clinical article",
abstract = "Object. The authors report novel imaging findings associated with the treatment of sorafenib (Nexavar) and sunitinib (Sutant), 2 agents used in the treatment of advanced metastatic disease. Methods. Patients with renal cell and breast carcinoma metastases to the brain were identified from the prospective database at the Penn State Hershey Medical Center and Penn State Cancer Institute. Results. Four patients who received sorafenib or sunitinib after surgical or radiosurgical treatment of their metastases were identified from the database. Clinical and/or radiographic changes consisting of seizures and cognitive or motor changes were described, associated with an increase in peritumoral edema and enhancement. These findings were observed to improve with discontinuation of the medications. Conclusions. The administration of sorafenib and sunitinib in patients with metastatic breast and renal cell carcinoma may lead to reversible clinical and imaging changes following surgical or radiosurgical treatment of their brain lesions. The authors hypothesize that leakage of the drug across a locally impaired blood-brain barrier contributes to peritumoral edema and inflammation, which may be erroneously interpreted as disease progression.",
author = "Hill, {Kenneth L.} and Lipson, {Adam C.} and Sheehan, {Jonas M.}",
year = "2009",
month = "12",
day = "7",
doi = "10.3171/2008.7.JNS08143",
language = "English (US)",
volume = "111",
pages = "497--503",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma : Clinical article. / Hill, Kenneth L.; Lipson, Adam C.; Sheehan, Jonas M.

In: Journal of neurosurgery, Vol. 111, No. 3, 07.12.2009, p. 497-503.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma

T2 - Clinical article

AU - Hill, Kenneth L.

AU - Lipson, Adam C.

AU - Sheehan, Jonas M.

PY - 2009/12/7

Y1 - 2009/12/7

N2 - Object. The authors report novel imaging findings associated with the treatment of sorafenib (Nexavar) and sunitinib (Sutant), 2 agents used in the treatment of advanced metastatic disease. Methods. Patients with renal cell and breast carcinoma metastases to the brain were identified from the prospective database at the Penn State Hershey Medical Center and Penn State Cancer Institute. Results. Four patients who received sorafenib or sunitinib after surgical or radiosurgical treatment of their metastases were identified from the database. Clinical and/or radiographic changes consisting of seizures and cognitive or motor changes were described, associated with an increase in peritumoral edema and enhancement. These findings were observed to improve with discontinuation of the medications. Conclusions. The administration of sorafenib and sunitinib in patients with metastatic breast and renal cell carcinoma may lead to reversible clinical and imaging changes following surgical or radiosurgical treatment of their brain lesions. The authors hypothesize that leakage of the drug across a locally impaired blood-brain barrier contributes to peritumoral edema and inflammation, which may be erroneously interpreted as disease progression.

AB - Object. The authors report novel imaging findings associated with the treatment of sorafenib (Nexavar) and sunitinib (Sutant), 2 agents used in the treatment of advanced metastatic disease. Methods. Patients with renal cell and breast carcinoma metastases to the brain were identified from the prospective database at the Penn State Hershey Medical Center and Penn State Cancer Institute. Results. Four patients who received sorafenib or sunitinib after surgical or radiosurgical treatment of their metastases were identified from the database. Clinical and/or radiographic changes consisting of seizures and cognitive or motor changes were described, associated with an increase in peritumoral edema and enhancement. These findings were observed to improve with discontinuation of the medications. Conclusions. The administration of sorafenib and sunitinib in patients with metastatic breast and renal cell carcinoma may lead to reversible clinical and imaging changes following surgical or radiosurgical treatment of their brain lesions. The authors hypothesize that leakage of the drug across a locally impaired blood-brain barrier contributes to peritumoral edema and inflammation, which may be erroneously interpreted as disease progression.

UR - http://www.scopus.com/inward/record.url?scp=70350507465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350507465&partnerID=8YFLogxK

U2 - 10.3171/2008.7.JNS08143

DO - 10.3171/2008.7.JNS08143

M3 - Article

C2 - 19199506

AN - SCOPUS:70350507465

VL - 111

SP - 497

EP - 503

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 3

ER -